[Acquired thrombotic thrombocytopenic purpura during durvalumab monotherapy for non-small cell lung cancer].
Rinsho Ketsueki
; 65(1): 24-29, 2024.
Article
en Ja
| MEDLINE
| ID: mdl-38311385
ABSTRACT
Immune checkpoint inhibitor (ICI)-induced thrombocytopenias are rare immune-related adverse events (irAE), but ICI-related thrombotic thrombocytopenic purpura (TTP) is extremely rare. A 79-year-old woman with non-small cell lung cancer received maintenance therapy with the anti-human PD-L1 monoclonal antibody durvalumab. Four weeks after the last infusion, she developed overt TTP. Remission was achieved by plasma exchange and prednisolone, and the patient has now been recurrence-free for over 12 months. To our knowledge, this is the first report of TTP occurring as an irAE of durvalumab.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Púrpura Trombocitopénica Trombótica
/
Carcinoma de Pulmón de Células no Pequeñas
/
Neoplasias Pulmonares
Tipo de estudio:
Diagnostic_studies
/
Etiology_studies
Límite:
Aged
/
Female
/
Humans
Idioma:
Ja
Revista:
Rinsho Ketsueki
Año:
2024
Tipo del documento:
Article